Siemens launches new efficient platform for drugs-of-abuse testing
Siemens Healthcare announced today the launch of its new drug-testing platform designed specifically to better meet the productivity, workflow and workspace needs of mid-volume laboratories.
The Viva-ProE System with EMIT technology, the standard in drug-testing assay performance, is now available globally from the Diagnostics Division of Siemens Healthcare. The system features a bench top design with compact footprint ideal for smaller workspaces and has a capacity for 50 sample positions, 12 auxiliary positions, and can run up to 133 EMIT tests per hour.
The touch screen monitor has intuitive, integrated software to enable ease of use for greater laboratory efficiency. There is a consolidated drug-testing menu for a drugs-of-abuse and validity testing, serum toxicology, and therapeutic and immunosuppressant drug monitoring. In addition, it includes onboard positive sample ID, sample and reagent probe crash protection and precision monitoring to enhance walk-away time and reduce errors, and convenient onboard waste and water storage to improve workflow.
For further information on the Viva-ProE System please visit http://www.healthcare.siemens.com/drug-testing-diagnostics/viva-drug-testing/viva-pro-e-system
Contact for journalists
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a leading provider of power transmission solutions and a pioneer in infrastructure solutions and automation and software solutions for industry. The company is also a leading supplier of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2013, which ended on September 30, 2013, revenue from continuing operations totaled €75.9 billion and income from continuing operations €4.2 billion. At the end of September 2013, Siemens had around 362,000 employees worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.